TY - JOUR
T1 - Endothelin subtype A receptor antagonist induces osteopenia in growing rats
AU - Tsukahara, Hirokazu
AU - Hori, Chikahide
AU - Hiraoka, Masahiro
AU - Yamamoto, Kazutaka
AU - Ishii, Yasushi
AU - Mayumi, Mitsufumi
N1 - Funding Information:
From the Department of Pediatrics and Department of Radiology, Fukui Medical School, Fukui, Japan. 'Submitted February \]7 , 1998; acceptedApri128, 1998. Supported by a research grant firm the Yokoyama Foundation, N(tgoya, Japan. !Address reprint requests to Hirokazu Tsukahara, MD, Department of Pediatrics, Fukui Medical School, Mat~uoka, Fukui 910-11, Japan. Copyright © 1998 by W.B. Saunders Company 0026-0495/98/4711-0019503.00/0
PY - 1998
Y1 - 1998
N2 - Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.
AB - Previous studies suggested that endothelin (ET) peptides are involved in bone metabolism. We examined the effects of long-term blockade of the ET(A) receptor, a receptor subtype primarily involved in the anabolic actions of ET, on bone mineral status in growing rats. Eight-week-old rats injected intraperitoneally with FR139317 50 mg/kg body weight, a specific ET(A) receptor antagonist, for 2 or 4 weeks were compared with control rats injected with vehicle only. Treatment with FR139317 caused a significant decrease in bone mass in the lumbar spine as determined by dual-energy x-ray absorptiometry (DXA). FR139317-induced osteopenia was associated with a significant decrease in the serum osteocalcin concentration but no change in the urinary excretion of pyridinium cross-links of collagen. Our findings indicate that long-term blockade of the ET(A) receptor reduces bone formation and induces osteopenia in growing rats. Our results suggest that ET produced by vascular endothelial cells plays an important role in bone growth and metabolism in vivo.
UR - http://www.scopus.com/inward/record.url?scp=0031724431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031724431&partnerID=8YFLogxK
U2 - 10.1016/S0026-0495(98)90313-4
DO - 10.1016/S0026-0495(98)90313-4
M3 - Article
C2 - 9826221
AN - SCOPUS:0031724431
SN - 0026-0495
VL - 47
SP - 1403
EP - 1407
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
IS - 11
ER -
